Inflammatory disorders

FDA approves Tremfya for ulcerative colitis

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis.

page 19 from 40